


ABSTRACT OF THE DISCLOSURE

This invention provides compounds defined by Formula I



5 or a pharmaceutically acceptable salt thereof,
wherein R¹, Q, R², R³, and R⁴ are as defined in the specification. The invention
also provides pharmaceutical compositions comprising a compound of Formula I,
or a pharmaceutically acceptable salt thereof, as defined in the specification,
together with a pharmaceutically acceptable carrier, diluent, or excipient. The
10 invention also provides methods of inhibiting an MMP-13 enzyme in an animal,
comprising administering to the animal a compound of Formula I, or a
pharmaceutically acceptable salt thereof. The invention also provides methods of
treating a disease mediated by an MMP-13 enzyme in a patient, comprising
administering to the patient a compound of Formula I, or a pharmaceutically
15 acceptable salt thereof, either alone or in a pharmaceutical composition. The
invention also provides methods of treating diseases such as heart disease,
multiple sclerosis, osteo- and rheumatoid arthritis, arthritis other than osteo- or
rheumatoid arthritis, cardiac insufficiency, inflammatory bowel disease, heart
failure, age-related macular degeneration, chronic obstructive pulmonary disease,
20 asthma, periodontal diseases, psoriasis, atherosclerosis, and osteoporosis in a
patient, comprising administering to the patient a compound of Formula I, or a
pharmaceutically acceptable salt thereof, either alone or in a pharmaceutical
composition. The invention also provides combinations, comprising a compound
of Formula I, or a pharmaceutically acceptable salt thereof, together with another
25 pharmaceutically active component as described in the specification.